GLP-1 Medications: Who Responds Best?

Key Takeaways

• Genetic differences in GLP-1 and GIP receptors may help explain why some people respond better to certain incretin medications than others, pointing toward a future of more personalized prescribing.
• A large network meta-analysis found GLP-1 receptor agonists and dual GLP-1/GIP agonists among the most effective drug options for weight loss in adults with overweight or obesity.
• Research suggests tirzepatide may be associated with a reduced risk of pulmonary embolism and deep vein thrombosis, though experts caution that more study is needed.
• GLP-1 therapy has been linked to meaningful shifts in food cravings and dietary quality, not just calorie reduction, according to the CRAVE study.
• Older adults face unique considerations—including muscle loss and fall risk—that make individualized medical supervision especially important when using GLP-1 medications.

What Are GLP-1 Medications and How Do They Work?

GLP-1 medications are a class of drugs that mimic a natural gut hormone to help regulate blood sugar, reduce appetite, and support weight loss. They work by activating specific receptors in the body that influence hunger signals, gastric emptying, and how your pancreas responds to meals.

The hormone they copy

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally releases after eating. It signals your brain that you're satisfied, prompts your pancreas to release insulin (which lowers blood sugar), and slows stomach emptying. GLP-1 medications deliver a longer-lasting, more potent version of this signal.

The main types available

• GLP-1 receptor agonists (GLP-1 RAs) — drugs like semaglutide (Ozempic®, Wegovy®) and liraglutide (Saxenda®) that activate only the GLP-1 receptor. A systematic review and network meta-analysis found these medications produce meaningful reductions in body weight compared with placebo.
• Dual agonists — tirzepatide (Mounjaro®, Zepbound®) activates both the GLP-1 receptor and GIP (glucose-dependent insulinotropic polypeptide). The same systematic review found dual agonists tend to produce greater weight loss than GLP-1-only medications.

What they do in your body

• Reduce appetite and cravings. People using GLP-1 RAs report significant reductions in food cravings and overall calorie intake, according to the CRAVE study.
• Improve dietary quality. The CRAVE study found participants shifted toward healthier food choices during treatment — eating differently, not just less.
• Support blood sugar control. By prompting insulin release only when blood sugar is elevated, these medications reduce the risk of dangerous blood sugar swings.

Why responses vary person to person

Not everyone experiences the same results. Genetic differences in GLP-1 and GIP receptors may influence how strongly a person responds to a given medication, according to research on incretin therapy personalization. This is why your experience may differ from someone else's — and why working closely with your prescriber matters.

---

Not medical advice. This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before starting, changing, or stopping any medication or health program.

Why Do Some People Respond Better Than Others?

No two people respond to GLP-1 medications and fasting in the same way — and that's not a personal failing. Differences in genetics, age, body composition, diet quality, and adherence to lifestyle changes all shape weight loss outcomes and how someone feels throughout treatment.

Genetics influence medication response. Your DNA affects how your body responds to GLP-1 drugs. Variations in genes controlling GLP-1 and GIP receptors — proteins on your cells where the medication binds — may make some people more or less sensitive to the drug's effects. Scientists are working toward matching people to the right medication based on their genetic profile, according to this review on incretin therapy personalization.

Diet quality during treatment matters significantly. GLP-1 medications reduce cravings, particularly for high-fat and high-sugar foods. People who also improve their overall diet quality during treatment see better results in body composition (the ratio of fat to muscle). The CRAVE study found that changes in food cravings and dietary intake during GLP-1 therapy were linked to meaningful shifts in eating patterns and body changes — meaning the medication works best when paired with real food improvements, not used alone.

Age affects outcomes, especially in older adults. Older adults may experience different benefits and risks on GLP-1 medications compared to younger people. Slower metabolism, age-related muscle loss, and other health conditions can all affect outcomes, according to this review on GLP-1 use in older adults. Fasting approaches may also require more careful adjustment in this group.

Medication type and dose influence results. Not all GLP-1 medications are identical. A large systematic review and network meta-analysis found meaningful differences in weight loss outcomes across different drugs and doses. So someone who doesn't respond well to one option may do better on another.

**Consistency with lifestyle habits amplifies results. The medication lowers the barrier by quieting hunger and reducing cravings. Still, people who pair it with regular fasting windows, better food choices, and movement tend to see stronger, more lasting results than those relying on the drug alone.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to your medication, diet, or fasting routine.

What Does Research Say About Weight Loss and Safety Outcomes?

Research shows that GLP-1 medications produce meaningful, clinically significant weight loss — and emerging evidence points to important safety benefits beyond the scale, including reduced risk of serious blood clots. Here's what the current science tells us.

---

Weight Loss: How Much Can You Expect?

A large systematic review and network meta-analysis — a study design that pools and compares results across many trials — found that GLP-1 receptor agonists (medications that mimic a gut hormone to reduce appetite and blood sugar) produced significantly greater weight loss than placebo and most other weight-loss drugs. Results varied by medication and dose, but evidence consistently favored these medications for meaningful body weight reduction in adults with overweight or obesity.

What Changes in Your Body and Eating Habits?

Weight loss with GLP-1 medications isn't just about eating less. The CRAVE study found that people on GLP-1 therapy experienced:

• Reduced food cravings, particularly for high-fat and sweet foods
• Improved dietary quality — people naturally shifted toward more nutritious food choices
• Changes in body composition, with a reduction in fat mass alongside weight loss

These shifts occurred without a structured diet program, suggesting the medication reshapes appetite signals. For people combining GLP-1 medications with fasting, this may make fasting periods feel more manageable by lowering hunger and cravings.

Safety Signals Worth Knowing

• Blood clot risk: A multicenter U.S. cohort study found that tirzepatide (a dual GIP/GLP-1 receptor agonist targeting two appetite-related hormones) was associated with a reduced risk of pulmonary embolism (blood clot in the lungs) and deep vein thrombosis (clot in a leg vein). This is a notable finding, though researchers note more study is needed.
• Cancer risk: A comparative study examining GLP-1 medications, bariatric surgery, and other weight-loss drugs found no clear increase in cancer risk associated with GLP-1 receptor agonists — a reassuring signal for long-term users.
• Older adults need extra attention: Research on older adults highlights unique considerations, including higher risk of muscle loss and nutritional deficiency, which may be amplified when fasting is added. Closer monitoring is recommended.

---

**Not medical advice. This section presents general research findings for informational purposes only. It is not a substitute for personalized guidance from a licensed healthcare provider. Talk to your doctor or care team before starting, changing, or combining any medication with fasting or dietary changes.

How Do GLP-1 Medications Change What You Eat and Crave?

GLP-1 medications don't just help you eat less — they actively reshape what you want to eat and how strongly food calls to you. Research shows that people on these medications report meaningful reductions in cravings, particularly for high-fat and high-sugar foods, alongside real improvements in overall diet quality.

Your cravings shift — especially for "junk" foods

The CRAVE study tracked people on GLP-1 receptor agonist therapy and found that food cravings decreased during treatment — with the biggest drops in cravings for fatty, sweet, and fast foods. This isn't willpower. The medication appears to change the reward signals your brain sends about certain foods.

You may naturally eat better quality food

The CRAVE study also found that dietary quality improved during GLP-1 therapy — meaning people tended to choose more nutritious foods overall, not just smaller portions of the same foods they ate before.

Appetite and fullness signals change

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally releases after eating to signal fullness to your brain. These medications mimic or boost that signal. The result: you feel full sooner, stay full longer, and feel less urgency to eat. According to research on special considerations in older adults, reduced appetite is one of the most consistent effects seen across GLP-1 medications.

What this means when you're also fasting:

• Fasting windows may feel more manageable because hunger between meals is genuinely reduced, not just suppressed by distraction
• You may notice less "food noise" — the constant background thinking about food that many people describe before starting these medications
• Smaller portions may feel satisfying in a way they didn't before
• The craving changes reported in the CRAVE study suggest your fasting breaks may naturally shift toward less processed, lower-fat choices — without forcing it

One important note: Because appetite drops significantly, getting enough protein, fiber, and key nutrients in fewer or smaller meals becomes genuinely important. The goal isn't just eating less — it's eating well within the smaller window your appetite now allows.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication or diet plan.

What Should Older Adults and Special Populations Know?

Older adults and people with certain health conditions need extra care when combining GLP-1 medications with fasting, because both can affect muscle mass, hydration, bone health, and blood sugar in ways that are more pronounced with age or existing illness. Here is what the research and clinical guidance say.

---

Older Adults (generally ages 65 and up)

GLP-1 medications reduce appetite significantly — and for older adults, that appetite suppression can tip into too little eating, raising the risk of sarcopenia (sar-ko-pee-nee-ah: the gradual loss of muscle mass and strength that naturally accelerates after age 60). A review focused on older adults highlights several specific concerns:

• Muscle loss: Rapid weight loss from GLP-1 therapy can reduce lean muscle, not just fat. Fasting amplifies this risk if protein intake drops too low.
• Bone density: Weight loss is linked to reduced bone mineral density. Older adults already face higher fracture risk.
• Dehydration: Reduced thirst sensation is common with aging. GLP-1-related nausea and fasting together can worsen fluid intake, raising dehydration risk.
• Hypoglycemia (hy-po-gly-SEE-mee-ah: blood sugar dropping too low): Older adults on diabetes medications alongside GLP-1 drugs face higher risk of dangerous low blood sugar, especially during fasting windows.

The same clinical review recommends that older adults prioritize resistance exercise (strength training) and adequate protein to protect muscle while on GLP-1 therapy — a recommendation that applies even more strongly when fasting is added.

---

People with Type 2 Diabetes

GLP-1 medications are commonly prescribed for type 2 diabetes. Adding fasting without medical supervision can cause blood sugar to fall unpredictably, particularly for anyone also taking insulin or sulfonylureas (a class of diabetes pill that lowers blood sugar independently). Dose adjustments are often needed — discuss this with your prescriber before starting any fasting routine.

---

People with a History of Eating Disorders

Fasting protocols can be psychologically triggering for people with a history of restrictive eating. GLP-1 medications already alter food cravings and dietary patterns, as shown in the CRAVE study. Combining them with structured fasting without professional support warrants extra caution.

---

⚠️ Not medical advice. This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual needs vary significantly. Always consult a qualified healthcare professional before starting, changing, or stopping any medication or dietary practice — especially if you are older, have diabetes, or have a history of eating disorders.

What Should You Know About Compounded GLP-1 Products?

Compounded GLP-1 products are copies of brand-name medications mixed by specialty pharmacies. While they may be cheaper or more accessible, they carry real quality and safety uncertainties that you should understand before choosing one.

What "compounded" means A compounded medication is one that a licensed pharmacy mixes from raw ingredients, usually to fill a gap when a brand-name drug is in short supply or to offer a different dose or form. Compounded versions of semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro, Zepbound) became widely available during recent shortage periods.

Why the market grew so fast Research found that compounded GLP-1 use was substantially more common than prescription records alone suggested, meaning many patients were using these products without their primary care team's full awareness. A separate study examining the post-shortage marketplace found a large number of online and telehealth vendors selling compounded GLP-1 products (source) in high-demand states, with wide variation in labeling, pricing, and product descriptions.

Key things to know before using a compounded product:

• No FDA approval for the compounded version. Brand-name GLP-1 medications undergo rigorous clinical trials. Compounded copies do not. The FDA does not review or approve the finished compounded product for safety, purity, or potency. -Ingredient quality can vary. Compounding pharmacies operate under different standards. Some are accredited and tightly regulated; others are not. Raw ingredients (called active pharmaceutical ingredients, or APIs) may come from different suppliers with different quality standards.
• Dosing is less standardized. Because compounded products are mixed to order, the dose you receive may differ from the label—higher or lower—which matters when you are also adjusting food intake through fasting.
• Your care team may not know you're using one. Studies found that compounded GLP-1 use was often missing from standard prescription records (source), creating gaps in your medical history that could affect other treatment decisions.

The practical bottom line If cost or access has led you to consider a compounded product, bring it up openly with your doctor or pharmacist. Ask which pharmacy is supplying it, whether it is accredited, and how the dose compares to the approved brand. Never adjust your dose without guidance, especially while fasting, when your calorie and nutrient intake is already reduced.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

FAQ

Can my genes affect how well a GLP-1 medication works for me?

Emerging research published in the Journal of the Endocrine Society (PMID 42487666) suggests that genetic variants in GLP-1 and GIP receptors may influence how individuals respond to incretin therapies. This field is still developing, and genetic testing is not yet standard practice—talk to your doctor about what personalized options may be available to you.

How do GLP-1 medications compare to other weight-loss drugs?

A 2025 systematic review and network meta-analysis in the BMJ (PMID 42419792) found that GLP-1 receptor agonists and dual GLP-1/GIP agonists ranked among the most effective pharmacological options for weight reduction in adults with overweight or obesity. Results varied by specific medication and individual factors, so a healthcare provider can help determine the best fit.

Is tirzepatide associated with any cardiovascular or clotting benefits?

A multicenter U.S. cohort study published in Frontiers in Endocrinology (PMID 42460324) found that tirzepatide was associated with a reduced risk of pulmonary embolism and deep vein thrombosis compared to certain other treatments. The researchers noted these findings are observational and that further research is needed before drawing firm conclusions.

Will a GLP-1 medication change what foods I want to eat?

The CRAVE study (PMID 42440974), published in Obesity Pillars, found that people on GLP-1 receptor agonist therapy reported changes in food cravings, dietary quality, and overall dietary intake—not just a reduction in total calories. Participants tended to shift toward less processed, higher-quality foods, though individual experiences varied.

Are compounded GLP-1 products safe and legal to use?

Research published in JAMA Health Forum (PMID 42467450) examined the compounded GLP-1 market in two states following drug shortages and found a significant number of products still being sold after brand-name availability was restored. Compounded medications are not FDA-approved and may differ in potency or purity. Always consult a licensed healthcare provider before using any compounded product.

What special risks do older adults face with GLP-1 medications?

A review in Advances in Therapy (PMID 42423951) highlighted that older adults using GLP-1 receptor agonists for obesity or type 2 diabetes face unique concerns, including accelerated muscle mass loss (sarcopenia), increased fall risk, and potential interactions with other medications. Individualized monitoring and nutritional support are considered especially important in this age group.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs, and fasting is not right for everyone — talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.